CD28 and systemic lupus erythematosus: CTLA-4 is a concern for SLE-related studies due to its inhibitory role in immune responses and control of hyperactive T and B cells, the mechanism of which may be through the interaction between auto-reactive B cells and CD4+ T cells and the CD28/CD80-86/CTLA-4 axis.